

Reply to: comment on “Meta-analysis of GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer”

Xiangzhen Kong¹

Received: 19 December 2016 / Accepted: 20 December 2016 / Published online: 22 February 2017
© Springer-Verlag Berlin Heidelberg 2017

Dear Editor,

It is our pleasure to see that other researchers have taken interest in our meta-analysis of GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer. We are also grateful to Drs. S. Gargnin and S. Terrazzino for their vigilance in noticing these two errors.

First, we agree that the three publications [Wang et al. *Genet Mol Res* 2015; Wang et al. *Genet Mol Res* 2015; Yuan et al. *Genet Mol Res* 2015 (5–7 of the Letter)] should have been included in this meta-analysis. Most likely, some errors have occurred in the process of downloading the relevant literatures. However, the inclusion of these three reports would not change the results of response to anthracycline-based chemotherapy, since the new included three articles did not concern anthracycline in chemotherapy.

Second, indeed, as emphasized by Drs. S. Gargnin and S. Terrazzino, the conclusions raised by Tables 1 and 3 of our original article are quite the opposite. In fact, the carriers of GG genotype of GSTP1rs1695 had a BETTER response to anthracycline-based chemotherapy than AA and AG genotypes (71.9 vs. 59.3%, respectively), and the GSTM1-present genotype could DECREASE the strength of response to chemotherapy compared with GSTM1-null genotype (58.9 vs. 65.8%, respectively).

We are happy to have the opportunity to rectify our first interpretation.

✉ Xiangzhen Kong
kongxzh12@aliyun.com

¹ School of Basic Medicine, Lanzhou University, No. 199,
Donggang West Road, Chengguan District, Lanzhou 730000,
Gansu, China